#58 Dr. Ingmar Gorman on MDMA-Assisted Psychotherapy for PTSD: A Potential Front-line Treatment

Therapy Show

Content provided by Host Dr. Bridget Nash. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Host Dr. Bridget Nash or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

3y ago 45:48

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on August 01, 2022 12:33 (2y ago). Last successful fetch was on May 26, 2021 04:26 (3y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.

Psychedelic-Assisted Psychotherapy is a technique that involves the use of drugs that produce a psychedelic effect in order to assist in the psychotherapy process. The U.S. Food and Drug Administration (FDA) named psilocybin-assisted therapy as a “breakthrough therapy.” Over the last two decades, researchers have received approval from governmental authorities to conduct trials on the use of the psychedelic substances to treat various conditions. What researchers have found is that psychedelic substances can have beneficial therapeutic effects. According to the research, there are a number of potential applications for psychedelic therapy such as anxiety, depression, substance use, alcohol use, and PTSD. At present, there are multiple clinical trials on psychedelic assisted therapy, some in phase II and III.

TherapyShow.com/Psychedelic-Assisted-Psychotherapy

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Twitter @Fluencetraining

Disclaimer: The information shared in this podcast is not a substitute for getting help from a mental health professional.

63 episodes